Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
2.
Mycoses ; 65(2): 239-246, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34874582

ABSTRACT

BACKGROUND: Blastomycosis is an endemic fungal infection that causes pulmonary and systemic disease. It can occur irrespective of the patient's immune status. The risk factors associated with the severity of the disease are not well studied. METHODS: This is a retrospective study of patients admitted with blastomycosis at the University of Kentucky Hospital from 2004 to 2019. Logistic regression was used to identify variables associated with severe blastomycosis. RESULTS: A total of 76 patients were identified; 22 (28.9%) had at least one immunosuppressive condition. Pulmonary blastomycosis was reported in 49/76 (65%) of the patients and disseminated infection in 27/76 (35.5%). All diagnostic tests were not significantly different in diagnostic results in immunocompromised vs immunocompetent patients. Cultures and histopathology were positive in 56/61 (91.8%) and 54/63 (85.7%) respectively. Blastomyces or Histoplasma antigen test was positive in 13/17 (76.4%) in immunocompromised patients compared to 26/42 (61.9%) in immunocompetent patients. Immunocompromised patients were more likely to be admitted to the hospital and ICU compared to immunocompetent patients. In the multivariate analysis, pulmonary multilobar disease (RR 5.68; 95% CI 2.13-15.15), obesity (RR 2.39; 95% CI 1.26-4.51), diabetes mellitus (RR 3.50; 95% CI 1.38-8.90) and immunosuppression (RR 2.28; 95% CI 1.14-4.56) were significant independent risk factors for severe blastomycosis. Inpatient mortality proportion was higher in immunocompromised patients but not statistically significant. CONCLUSION: Pulmonary multilobar disease, obesity, diabetes mellitus and immunosuppression were risk factors associated with severe blastomycosis. Immunocompromised patients required more frequent hospitalisations compared to immunocompetent patients.


Subject(s)
Blastomycosis , Blastomyces , Blastomycosis/diagnosis , Blastomycosis/epidemiology , Diabetes Mellitus/epidemiology , Humans , Immunocompromised Host , Immunosuppression Therapy/adverse effects , Lung Diseases/epidemiology , Obesity/epidemiology , Retrospective Studies , Risk Factors
3.
Mycoses ; 64(9): 1073-1082, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34033158

ABSTRACT

BACKGROUND: Cryptococcosis is classically associated with the immunocompromised patients but there is a rising appreciation for its impact on the immunocompetent hosts. We sought to analyse the trends, diagnosis, treatment of different hosts and the effect of immunodeficiency and chronic liver disease on relapse and in-house mortality. METHODS: This is a retrospective study of 12 years of patients with cryptococcosis, divided into three different groups: HIV-infected, transplant and non-HIV non-transplant (NHNT). Data were analysed with Chi-square, unpaired parametric t test, simple and multivariate logistic regression analysis. RESULTS: Of 114 identified patients, 23 (20.2%) had HIV infection, 11 (9.6%) had transplant, 80 (70.2%) were NHNT patients. Overall, mortality was 28.1% (32/114) and relapse occurred in 10.5% (12/114) of patients. The mortality trend was higher (OR = 2.346, p = .287) in the transplant group (45.5%, 5/11) than in HIV (26.1%, 6/23) and NHNT groups (26.3%, 21/80). HIV was associated with relapse; 30.4% (7/23) for HIV-positive patients and 5.5% (5/91) for HIV-negative patients (OR = 7.525, p = .002). Chronic liver disease had a large and statistically significant association with mortality on multivariate analysis (OR = 3.583, p = .013) which was more pronounced than the HIV or transplant groups. It was independently associated with mortality by chi-square analysis (OR 3.137, p = .012). CONCLUSION: Chronic liver disease represented 30.7% (35/114) of all studied patients. It was a risk factor for in-hospital mortality. HIV infection and transplant were not statistically significant for mortality. Relapse was highest in the HIV-infected patients at 30.4% (7/23). These data highlight the effect of type and degree of immunocompromise on cryptococcosis.


Subject(s)
Cryptococcosis , End Stage Liver Disease , HIV Infections , Cryptococcosis/epidemiology , Cryptococcosis/mortality , End Stage Liver Disease/epidemiology , HIV Infections/epidemiology , Humans , Recurrence , Retrospective Studies , Risk Factors , Tertiary Care Centers
5.
Int J Antimicrob Agents ; 54(2): 249-254, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31071467

ABSTRACT

PURPOSE: Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly widespread in the healthcare system, resulting in infections associated with mortality of up to 50%. Many laboratories use automated systems to identify CRE isolates and determine susceptibility. The aim of this study was to evaluate categorical agreement between the BD Phoenix automated system and the gold standard - broth microdilution - in determining minimum inhibitory concentrations of CRE. METHODOLOGY: The activity of amikacin, aztreonam, cefepime, ceftazidime, ertapenem, gentamicin, levofloxacin, meropenem, nitrofurantoin, piperacillin-tazobactam and tobramycin on 125 CRE isolates collected from an academic medical centre was evaluated. Categorical agreement between BD Phoenix and broth microdilution was determined, as well as minor error rates, major error rates and very major error rates. RESULTS: BD Phoenix significantly overestimates susceptibility of CRE isolates to amikacin, aztreonam, cefepime, ceftazidime, gentamicin, levofloxacin, meropenem, nitrofurantoin and tobramycin compared with broth microdilution. Overall, categorical agreement of 76% between testing methods indicates the potential diminished ability of BD Phoenix to predict resistance accurately in highly drug-resistant isolates. All tested antimicrobials had higher major error rates compared with previous literature. CONCLUSIONS: BD Phoenix has diminished ability to determine susceptibility of CRE isolates. Further studies are warranted in order to validate BD Phoenix susceptibility testing in highly resistant CRE isolates. The mechanism by which isolates are resistant to carbapenems does not impact the ability of BD Phoenix to determine susceptibility.


Subject(s)
Anti-Bacterial Agents/pharmacology , Automation, Laboratory/methods , Carbapenem-Resistant Enterobacteriaceae/drug effects , Enterobacteriaceae Infections/microbiology , Microbial Sensitivity Tests/methods , Academic Medical Centers , Humans
7.
Biomed Res Int ; 2016: 2737295, 2016.
Article in English | MEDLINE | ID: mdl-27631004

ABSTRACT

Rhodococcus equi is an unusual zoonotic pathogen that can cause life-threatening diseases in susceptible hosts. Twelve patients with R. equi infection in Kentucky were compared to 137 cases reported in the literature. Although lungs were the primary sites of infection in immunocompromised patients, extrapulmonary involvement only was more common in immunocompetent patients (P < 0.0001). Mortality in R. equi-infected HIV patients was lower in the HAART era (8%) than in pre-HAART era (56%) (P < 0.0001), suggesting that HAART improves prognosis in these patients. Most (85-100%) of clinical isolates were susceptible to vancomycin, clarithromycin, rifampin, aminoglycosides, ciprofloxacin, and imipenem. Interestingly, there was a marked difference in susceptibility of the isolates to cotrimoxazole between Europe (35/76) and the US (15/15) (P < 0.0001). Empiric treatment of R. equi infection should include a combination of two antibiotics, preferably selected from vancomycin, imipenem, clarithromycin/azithromycin, ciprofloxacin, rifampin, or cotrimoxazole. Local antibiograms should be checked prior to using cotrimoxazole due to developing resistance.


Subject(s)
Actinomycetales Infections/immunology , Actinomycetales Infections/microbiology , Anti-Bacterial Agents/pharmacology , Rhodococcus equi/drug effects , Rhodococcus equi/isolation & purification , Actinomycetales Infections/drug therapy , Actinomycetales Infections/mortality , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Demography , Female , Humans , Immunocompetence/drug effects , Immunocompromised Host , Male , Microbial Sensitivity Tests , Middle Aged , Organ Specificity
8.
Open Forum Infect Dis ; 3(1): ofv205, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26835478

ABSTRACT

Mycobacterium marinum infection has been historically associated with exposure to aquariums, swimming pools, fish, or other marine fauna. We present a case of M marinum left wrist tenosynovitis and elbow bursitis associated with a puncture injury and exposure to coal mine water in Illinois.

9.
Med Mycol Case Rep ; 10: 4-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26779419

ABSTRACT

Geotrichum species have been rarely reported as the cause of sepsis, disseminated infection in immunosuppressed patients. The patient we describe developed indolent endophthalmitis four months after her routine right eye cataract surgery. The intraoperative sample from right vitreous fluid grew Geotrichum candidum. The patient underwent vitrectomy, artificial lens explantation and intravitreal injection of amphotericin B followed by oral voriconazole. Despite these interventions, she underwent enucleation. This is the first published case of Geotrichum candidum endophthalmitis.

10.
J Int Assoc Provid AIDS Care ; 13(2): 100-5, 2014.
Article in English | MEDLINE | ID: mdl-24029651

ABSTRACT

The impact of highly active antiretroviral therapy (HAART) on the epidemiology of AIDS-associated histoplasmosis in the past decade is poorly defined. Among 100 patients with histoplasmosis in an endemic region between 2000 and 2009, 42 patients were immunocompetent, 32 were infected with HIV, and 26 were non-HIV-immunocompromised patients. The percentage with HIV decreased 67% in 2000-2001 to 18% in 2008-2009 (P = .004), while the proportion of non-HIV immunocompromised patients increased, 8% to 41% (P = .14). Histoplasma antigen was the most sensitive test (73%), whereas potassium hydroxide examination of clinical specimens was the least sensitive test (33%) in all 3 groups. Bronchoalveloar fluid culture (74%) had the highest yield among the cultures. The relapse rate was higher in HIV-infected patients compared to the other 2 groups (P = .04). The epidemiology of histoplasmosis in our endemic area has changed during the era of HAART. Organ transplantation and increasing use of immunosuppressive agents for chronic inflammatory conditions in non-HIV patients now account for most of the cases of histoplasmosis.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , HIV Infections/immunology , Histoplasmosis/immunology , Immunocompetence/immunology , Immunocompromised Host/immunology , Immunosuppressive Agents/immunology , AIDS-Related Opportunistic Infections/epidemiology , Adult , Aged , Antiretroviral Therapy, Highly Active , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , Histoplasmosis/complications , Histoplasmosis/epidemiology , Hospital Mortality , Humans , Immunosuppressive Agents/therapeutic use , Kentucky/epidemiology , Kidney Transplantation , Male , Middle Aged , Recurrence , Tertiary Care Centers , Time Factors
12.
South Med J ; 105(5): 283-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22561543

ABSTRACT

Lemierre's syndrome is an uncommon complication of pharyngitis in the United States and caused most commonly by the bacterium Fusobacterium necrophorum. The syndrome is characterized by a history of recent pharyngitis followed by ipsilateral internal jugular vein thrombosis and metastatic pulmonary abscesses and is a disease for which patients will seek medical care and advice. As most patients are admitted to the hospital under internal medicine, practitioners should be familiar with the usual signs and symptoms of Lemierre's syndrome along with its diagnosis and treatment. Controversy involves the choice and duration of antimicrobial therapy used for treatment and anticoagulation therapy for internal jugular vein thrombosis. As the diagnosis and management of this syndrome has generated controversy, an updated review of the literature and treatment recommendations may be helpful for providing optimal care for patients with this often unrecognized and confusing infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Fusobacterium Infections/complications , Fusobacterium necrophorum , Lemierre Syndrome , Pharyngitis/complications , Fusobacterium Infections/diagnosis , Fusobacterium Infections/drug therapy , Humans , Lemierre Syndrome/diagnosis , Lemierre Syndrome/epidemiology , Lemierre Syndrome/etiology , Lemierre Syndrome/therapy , Pharyngitis/microbiology
14.
Clin Infect Dis ; 53(5): 448-54, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21810734

ABSTRACT

BACKGROUND: The sensitivity of the MVista Histoplasma antigen enzyme immunoassay (MiraVista Diagnostics) has been evaluated in disseminated histoplasmosis in patients with AIDS and in the "epidemic" form of acute pneumonia. Moreover, there has been no evaluation of the sensitivity of antigenemia detection in disseminated histoplasmosis after the implementation of methods to dissociate immune complexes and denature released antibodies. The goal of this study was to determine the sensitivity of the current antigen assay in different categories of histoplasmosis. METHODS: Urine and serum specimens obtained from 218 patients with histoplasmosis and 229 control subjects, including 30 with blastomycosis, were tested. RESULTS: Antigenuria was detected in 91.8% of 158 patients with disseminated histoplasmosis, 83.3% of 6 patients with acute histoplasmosis, 30.4% of 46 patients with subacute histoplasmosis, and 87.5% of 8 patients with chronic pulmonary histoplasmosis; antigenemia was present in 100% of 31 tested cases of disseminated histoplasmosis. Among patients with disseminated cases, antigenuria was detected more often and at higher concentrations in immunocompromised patients and those with severe disease. Specificity was 99.0% for patients with nonfungal infections (n = 130) and in healthy subjects (n = 69), but cross-reactivity occurred in 90% of patients with blastomycosis. CONCLUSIONS: The sensitivity of antigen detection in disseminated histoplasmosis is higher in immunocompromised patients than in immunocompetent patients and in patients with more severe illness. The sensitivity for detection of antigenemia is similar to that for antigenuria in disseminated infection.


Subject(s)
Antigens, Fungal/blood , Antigens, Fungal/urine , Histoplasma/immunology , Histoplasmosis/diagnosis , Immunoenzyme Techniques/methods , Antibodies, Fungal , Case-Control Studies , Cohort Studies , Cross Reactions , Histoplasma/isolation & purification , Histoplasmosis/pathology , Humans , Immunocompromised Host , Immunoenzyme Techniques/standards , Lung Diseases, Fungal/diagnosis , Lung Diseases, Fungal/microbiology , Mycological Typing Techniques , Sensitivity and Specificity
15.
Biol Blood Marrow Transplant ; 15(8): 991-5, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19589489

ABSTRACT

Posaconazole is a triazole with broad spectrum of activity against multiple fungi including members of the fungal order Mucorales. This activity has been shown both in clinical and in vitro studies, which are critically reviewed here. It has become very popular in prophylaxis in acute myelogenous leukemia (AML) induction and in the graft-versus-host disease (GVHD) settings after 2 recent prospective trials that showed advantage of posaconazole prophylaxis compared to fluconazole or itraconazole. In this report, 2 patients are presented, in whom, despite posaconazole prophylaxis, invasive and ultimately fatal Rhizopus pulmonary infections developed. These cases are similar to a previously reported case of Rhizopus infection in a stem cell transplant recipient who also received posaconazole, indicating a potential newly recognized pattern of breakthrough infections in patients receiving posaconazole prophylaxis.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Pneumonia/etiology , Rhizopus , Triazoles/therapeutic use , Antifungal Agents/therapeutic use , Chemoprevention/methods , Fatal Outcome , Humans , Male , Middle Aged , Mucormycosis/etiology , Pneumonia/microbiology , Transplantation, Homologous
16.
J Pediatr Adolesc Gynecol ; 21(6): 373-6, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19064233

ABSTRACT

OBJECTIVE: To test the feasibility of a brief, clinic-based, behavioral intervention designed to foster the adoption of three protective behaviors among adolescent females testing positive for any of 13 oncogenic strains of HPV. This feasibility study also included non-statistical comparisons of risk behaviors assessed at follow-up. DESIGN: A non-randomized clinical trial. PARTICIPANTS: Twenty-eight sexually active, 17-23-year-old females were recruited from a hospital-based adolescent medicine clinic. INTERVENTION: Adolescents testing positive for HPV received a physician-delivered intervention designed to emphasize the association of high-risk HPV with cervical cancer and to promote protective behaviors. Those testing negative for HPV did not receive intervention. MAIN OUTCOME MEASURE: Several indicators were used including sexual risk behaviors, intent for subsequent Pap testing, intent to quit smoking, and intent to be vaccinated against HPV. RESULTS: Those testing positive (39.3%) received the intervention. Recruitment and retention rates were high. In comparing the two groups after a 30-day follow-up period, modest differences, favoring the intervention, were observed. At follow-up, teens testing positive reported lower levels of risk taking behavior, greater intent to return for next Pap testing, greater intent to quit smoking (if applicable), and greater intent to be vaccinated against HPV. CONCLUSION: Overall, the findings suggest that a larger study is indeed feasible and may produce meaningful differences between groups. Although the source (i.e., testing positive vs. the receipt of intervention) of these differences cannot be determined, findings suggests that further investigation of a testing/behavioral intervention regarding HPV and cervical cancer prevention for adolescent females may be warranted.


Subject(s)
Health Behavior , Papillomavirus Infections/psychology , Risk-Taking , Adolescent , Feasibility Studies , Female , Humans , Risk Assessment , Risk Factors , Young Adult
18.
Am J Clin Pathol ; 128(4): 622-7, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17875514

ABSTRACT

Disseminated strongyloidiasis is often associated with enteric bacterial infections. This study was undertaken to determine if enteric organisms caused extraintestinal infections in patients infected with Strongyloides stercoralis but without apparent dissemination. The medical records of hospitalized patients from central Kentucky with strongyloidiasis (1993-2003) were examined to determine the occurrence of extraintestinal infections with enteric organisms. Of 30 patients with S stercoralis, 16 had invasive infections, including sepsis, meningitis, pneumonia, peritonitis, and endocarditis caused by enteric bacteria and Candida organisms. Infections were seen in 8 (62%) of 13 patients with disseminated strongyloidiasis and 8 (47%) of 17 with disease apparently limited to the gastrointestinal tract. Fifteen patients were receiving corticosteroids or other immunosuppressive therapy. Peripheral eosinophilia was seen in only 23% (7/30). Infection with S stercoralis, even without obvious dissemination, may predispose to invasive infections caused by enteric organisms. In Strongyloides-endemic areas, patients with invasive infections caused by enteric organisms should be examined for coinfection with S stercoralis.


Subject(s)
Bacteremia/complications , Enterobacteriaceae Infections/complications , Fungemia/complications , Opportunistic Infections/complications , Strongyloides stercoralis/pathogenicity , Strongyloidiasis/complications , Adolescent , Adult , Aged , Animals , Bacteremia/diagnosis , Bacteremia/mortality , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/mortality , Female , Fungemia/diagnosis , Fungemia/mortality , Hospitalization , Humans , Kentucky/epidemiology , Male , Middle Aged , Opportunistic Infections/diagnosis , Opportunistic Infections/mortality , Strongyloidiasis/diagnosis , Strongyloidiasis/mortality , Survival Rate
19.
Arch Pathol Lab Med ; 130(12): 1843-6, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17149961

ABSTRACT

CONTEXT: Pseudallescheria boydii is being increasingly isolated in immunocompromised patients. OBJECTIVE: To present 24 years of data on patients from whom P. boydii was isolated. DESIGN: Retrospective review of archival laboratory data and patient charts at a tertiary care hospital with a full service mycology laboratory. All patients evaluated from whom P. boydii was isolated between 1980 and 2003 were included in this study. RESULTS: Twenty-four patients from whom P. boydii had been isolated were identified. The majority of cases represented pulmonary involvement, particularly in cystic fibrosis patients. Three additional patients had infections in surgical or traumatic lesions of the head and 4 had disseminated disease. Invasive disease was associated with underlying malignancy or transplantation and resulted in death secondary to the fungal infection in the majority of cases. CONCLUSIONS: Pseudallescheria boydii may cause significant disease in humans. Invasive infections with P. boydii are often misdiagnosed and inadequately treated. Aggressive treatment of locally invasive disease may be of value in preventing rapid and fatal dissemination with this organism.


Subject(s)
Lung Diseases, Fungal/pathology , Mycetoma/pathology , Pseudallescheria/isolation & purification , Cystic Fibrosis/epidemiology , Cystic Fibrosis/microbiology , Cystic Fibrosis/pathology , Hospitals, University , Humans , Immunocompromised Host , Kentucky/epidemiology , Lung Diseases, Fungal/epidemiology , Lung Diseases, Fungal/microbiology , Mycetoma/complications , Mycetoma/epidemiology , Retrospective Studies
20.
Orthopedics ; 28(11): 1322-5, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16295189

ABSTRACT

As more and more gram-negative bacteria produce extended-spectrum beta-lactamases, it is important that physicians know what to do when these bacteria cause postoperative infections in patients.


Subject(s)
Bacteria/enzymology , Sepsis/metabolism , Surgical Wound Infection/microbiology , beta-Lactamases/metabolism , Escherichia coli/enzymology , Humans , Klebsiella pneumoniae/enzymology , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...